Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
ES2525772B2 - Síntesis y uso de perimidinonas en trastornos del estado del ánimo y ansiedad - Google Patents
[go: Go Back, main page]

ES2525772B2 - Síntesis y uso de perimidinonas en trastornos del estado del ánimo y ansiedad - Google Patents

Síntesis y uso de perimidinonas en trastornos del estado del ánimo y ansiedad Download PDF

Info

Publication number
ES2525772B2
ES2525772B2 ES201431468A ES201431468A ES2525772B2 ES 2525772 B2 ES2525772 B2 ES 2525772B2 ES 201431468 A ES201431468 A ES 201431468A ES 201431468 A ES201431468 A ES 201431468A ES 2525772 B2 ES2525772 B2 ES 2525772B2
Authority
ES
Spain
Prior art keywords
anxiety
mood disorders
perimidinones
synthesis
mood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201431468A
Other languages
English (en)
Other versions
ES2525772A1 (es
Inventor
Eduardo Sobarzo Sánchez
Eugenio Uriarte Villares
José Ángel FONTENLA GIL
Brais RODRÍGUEZ FIDALGO
Marta CIMADEVILA FONDEVILA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Original Assignee
Universidade de Santiago de Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Santiago de Compostela filed Critical Universidade de Santiago de Compostela
Priority to ES201431468A priority Critical patent/ES2525772B2/es
Publication of ES2525772A1 publication Critical patent/ES2525772A1/es
Application granted granted Critical
Publication of ES2525772B2 publication Critical patent/ES2525772B2/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Síntesis y uso de perimidinonas en trastornos del estado del ánimo y ansiedad. La presente invención se refiere a compuestos de fórmula I y a composiciones farmacéuticas que comprenden estos alcaloides para su uso en trastornos del estado del ánimo y ansiedad.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
-
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19

Claims (1)

  1. imagen1
    imagen2
ES201431468A 2014-10-03 2014-10-03 Síntesis y uso de perimidinonas en trastornos del estado del ánimo y ansiedad Active ES2525772B2 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201431468A ES2525772B2 (es) 2014-10-03 2014-10-03 Síntesis y uso de perimidinonas en trastornos del estado del ánimo y ansiedad

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201431468A ES2525772B2 (es) 2014-10-03 2014-10-03 Síntesis y uso de perimidinonas en trastornos del estado del ánimo y ansiedad

Publications (2)

Publication Number Publication Date
ES2525772A1 ES2525772A1 (es) 2014-12-29
ES2525772B2 true ES2525772B2 (es) 2015-04-16

Family

ID=52105570

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201431468A Active ES2525772B2 (es) 2014-10-03 2014-10-03 Síntesis y uso de perimidinonas en trastornos del estado del ánimo y ansiedad

Country Status (1)

Country Link
ES (1) ES2525772B2 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100293286A1 (en) * 2007-09-13 2010-11-18 Ant - Advanced Network Technologies Oy Method and system for wireless real-time collection of multichannel digital audio
ES2402132B1 (es) * 2011-10-04 2014-06-10 Universidade De Santiago De Compostela Nanocapsulas de oxoisoaporfinas para el tratamiento de la depresion

Also Published As

Publication number Publication date
ES2525772A1 (es) 2014-12-29

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
ECSP16071151A (es) Inhibidores de dihidropirrolopiridina de ror-gamma
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
DOP2015000274A (es) Compuestos químicos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
HUE043440T2 (hu) Policiklusos amidszármazékok mint CDK9 inhibitorok
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
ES2421956B1 (es) Nueva forma cristalina de sulfato de sitagliptina
HUE049502T2 (hu) Policiklusos vegyületek mint bruton-tirozin-kináz inhibitorok
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
EA201892430A1 (ru) Синтез индазолов
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
HRP20260155T1 (hr) Kx2‑391/kx‑01 za upotrebu u liječenju aktinične keratoze
ES2641554T3 (es) Kit de piezas para colocación de anclaje quirúrgico
BR112016012552A8 (pt) derivado de cromona como um antagonista do receptor d3 de dopamina, seu uso e sua composição farmacêutica
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2525772

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20150416